Lamivudine CAS 134678-17-4

Basic information
CAS No:134678-17-4                                                          Einecs No.:   N/A
Character:White to off-white  powder                           MF:C8H11N3O3S
MW:229.25                                                                         Purity:99%
Quality Guarantee Period:Two Years Min                      Grade Standard:enterprise standard
Sample:10-20g Free Sample                                             Brand Name:Wongpharm



Lamivudine CAS 134678-17-4
Specification: USP
Molecular formula:C8H11N3O3S
Character:White to off-white  powder
 

pharmacological toxicology:
lamivudine is a nucleoside antivirals.It has a strong inhibitory effect on the hepatitis b virus in vitro and in experimental infected animals.Lamivudine may be metabolized within infected cells and normal cells lamivudine triphosphate, it is the active form of lamivudine, is viral polymerase inhibitors, can quickly inhibit the replication of the virus.Lamivudine triphosphate seeps into the viral DNA strand and blocks the synthesis of viral DNA.Lamivudine triphosphate does not interfere with the metabolism of normal cell deoxynucleoside, and the inhibition of DNA polymerase alpha and beta in mammalian DNA has little effect on the DNA content of mammalian cells.Lamivudine has no obvious toxicity to mitochondrial structure, DNA content and function

pharmacokinetics:
 lamivudine was well absorbed after oral administration, and oral lamivudine 0.1g was estimated to be about 1 hour for blood peak concentration (Cmax), 1.1 ~ 1.5 ug/ml, and biological utilization was 80% ~ 85 %.Lamivudine and food can delay between 0.25 ~ 2.5 hours and the concentration of blood drug peak (Cmax) by 10 ~ 40%, but the bioavailability remains unchanged.Intravenous drug research results show that the average distribution of lamivudine (Vd) volume of 1.3 L/kg, average system clearance of 0.3 L/h/kg, lamivudine (70%), mainly by the organic cation transport system by renal clearance, blood elimination half-life (t1/2)
For 5 to 7 hours.The pharmacokinetic kinetics of lamivudine was linear in the therapeutic dose range, and the plasma protein binding rate was low.In vitro studies showed that the binding rate of serum albumin was <16% ~ 36%.Lamivudine can enter the cerebrospinal fluid through the blood-cerebrospinal barrier barrier.
Lamivudine is mainly based on the renal excretion of the drug prototype, and the renal excretion is about 70% of the total clearance, and only 5% ~ 10% is metabolized into the derivative of the anti-sulfur oxide.


drug interaction:
1. Lamivudine and have the same discharge mechanism of drugs (such as methyl benzyl oxygen organism, sulfamethoxazole) at the same time, when using lamivudine blood levels can be increased by 40%, but is damage to kidney function.
2. The concentration of blood drug peaks (Cmax) of the latter can be increased with zidovudine, but it does not affect the area under the curve of the elimination and drug.

Indications:
It is applicable to all kinds of virus infection
Usage and dosage:
take oral, 2 mg/kg weight, 1 time a day.
Storage:
shade, seal, kept in a cool, dry place
Package:10kg/drum

 

specification

Basic information
CAS No:134678-17-4                                                          Einecs No.:   N/A
Character:White to off-white  powder                           MF:C8H11N3O3S
MW:229.25                                                                         Purity:99%
Quality Guarantee Period:Two Years Min                      Grade Standard:enterprise standard
Sample:10-20g Free Sample                                             Brand Name:Wongpharm



Lamivudine CAS 134678-17-4
Specification: USP
Molecular formula:C8H11N3O3S
Character:White to off-white  powder
 

pharmacological toxicology:
lamivudine is a nucleoside antivirals.It has a strong inhibitory effect on the hepatitis b virus in vitro and in experimental infected animals.Lamivudine may be metabolized within infected cells and normal cells lamivudine triphosphate, it is the active form of lamivudine, is viral polymerase inhibitors, can quickly inhibit the replication of the virus.Lamivudine triphosphate seeps into the viral DNA strand and blocks the synthesis of viral DNA.Lamivudine triphosphate does not interfere with the metabolism of normal cell deoxynucleoside, and the inhibition of DNA polymerase alpha and beta in mammalian DNA has little effect on the DNA content of mammalian cells.Lamivudine has no obvious toxicity to mitochondrial structure, DNA content and function

pharmacokinetics:
 lamivudine was well absorbed after oral administration, and oral lamivudine 0.1g was estimated to be about 1 hour for blood peak concentration (Cmax), 1.1 ~ 1.5 ug/ml, and biological utilization was 80% ~ 85 %.Lamivudine and food can delay between 0.25 ~ 2.5 hours and the concentration of blood drug peak (Cmax) by 10 ~ 40%, but the bioavailability remains unchanged.Intravenous drug research results show that the average distribution of lamivudine (Vd) volume of 1.3 L/kg, average system clearance of 0.3 L/h/kg, lamivudine (70%), mainly by the organic cation transport system by renal clearance, blood elimination half-life (t1/2)
For 5 to 7 hours.The pharmacokinetic kinetics of lamivudine was linear in the therapeutic dose range, and the plasma protein binding rate was low.In vitro studies showed that the binding rate of serum albumin was <16% ~ 36%.Lamivudine can enter the cerebrospinal fluid through the blood-cerebrospinal barrier barrier.
Lamivudine is mainly based on the renal excretion of the drug prototype, and the renal excretion is about 70% of the total clearance, and only 5% ~ 10% is metabolized into the derivative of the anti-sulfur oxide.


drug interaction:
1. Lamivudine and have the same discharge mechanism of drugs (such as methyl benzyl oxygen organism, sulfamethoxazole) at the same time, when using lamivudine blood levels can be increased by 40%, but is damage to kidney function.
2. The concentration of blood drug peaks (Cmax) of the latter can be increased with zidovudine, but it does not affect the area under the curve of the elimination and drug.

Indications:
It is applicable to all kinds of virus infection
Usage and dosage:
take oral, 2 mg/kg weight, 1 time a day.
Storage:
shade, seal, kept in a cool, dry place
Package:10kg/drum

 

specification

Veterinary Ultrasound Scanner

As customers have higher and higher requirements for animal reproduction and animal disease diagnosis and treatment, traditional diagnostic methods such as visual inspection, stethoscope listening, thermometer inspection, and percussion and hammering can no longer meet the needs of animal husbandry production and veterinary clinics. Today, B-ultrasound is playing a big role in human medical diagnosis, and in the future, B-ultrasound will also play a role in animal medicine. We should promote the use of veterinary ultrasound scanner step by step according to the actual situation, popularize the knowledge of the use of veterinary ultrasound scanner, take this as an opportunity, and use it as a ladder to improve the level of veterinary practice in our country.

Veterinary Ultrasound Scanner,Vet Ultrasound Scanner,Veterinary Ultrasound Machine,Veterinary Ultrasound Equipment

Mianyang United Ultrasound Electronics Co., Ltd , https://www.ultrasonicequip.com